37 results on '"Mjörnstedt, Lars"'
Search Results
2. Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
3. #1985 Tocilizumab in chronic active antibody-mediated rejection: a randomized controlled open-label multi-center trial (INTERCEPT study)
4. Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy
5. Oral and lip cancer in solid organ transplant patients – A cohort study from a Swedish Transplant Centre
6. Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial
7. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation
8. Steroid-resistant rejection in kidney-transplanted patients: is ATG treatment for three or ten days preferable?
9. Endoluminal laser-Doppler measurements of jejunal perfusion in patients undergoing liver transplantation
10. IMPROVED RENAL FUNCTION BY OVERNIGHT SWITCH FROM CYCLOSPORINE TO EVEROLIMUS AT WEEK 7 AFTER RENAL TRANSPLANTATION. ONE YEAR RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL: LB-O-004
11. P1657GRAFT- AND PATIENT-SURVIVAL IN TRANSPLANT KIDNEY PATIENTS UNDERGOING TRANSPLANT BIOPSIES
12. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study
13. More on B-Cell–Depleting Induction Therapy and Acute Cellular Rejection
14. The risk of graft loss 5 years after kidney transplantation is increased if cold ischemia time exceeds 14 hours
15. Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial
16. Safety and efficacy of eculizumab for the prevention of antibody‐mediated rejection after deceased‐donor kidney transplantation in patients with preformed donor‐specific antibodies
17. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation
18. An in-progress, open-label, multi-centre study (SAILOR) evaluating whether a steroid-free immunosuppressive protocol, based on ATG induction and a low tacrolimus dose, reduces the incidence of new onset diabetes after transplantation
19. A Randomized, Double-Blind, Placebo-Controlled Study of Single Dose Rituximab as Induction in Renal Transplantation
20. Authors' Reply to Letter by van den Hoogen and Hilbrands
21. A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation
22. Incidence of End-Stage Renal Disease Among Live Kidney Donors
23. ABO‐incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti‐CD20 antibody treatment
24. Adult ABO‐incompatible liver transplantation, using A2 and B donors
25. Increasing prevalence of cardiovascular disease in kidney transplant patients with Type 1 diabetes
26. Adult ABO-incompatible liver transplantation, using A2 and B donors.
27. Prolonged Rat Heart Allograft Survival after Treatment with Angiotensin Converting Enzyme Inhibitor or a Calcium Antagonist.
28. Effect of FK 506 and lipo prostaglandin E1 on heart allograft survival in rats.
29. Characteristics of the Induction Phase of Antithymocyte-Globulin-Induced Heart Allograft Tolerance in the Rat.
30. Induction of Long-Term Heart Allograft Survival in the Rat by Rabbit ATG.
31. MECHANISMS MAINTAINING TRANSPLANTATION TOLERANCE IN ANTITHYMOCYTE GLOBULIN-TREATED RATS.
32. Endoluminal laser-Doppler measurements of jejunal perfusion in patients undergoing liver transplantation
33. MECHANISMS MAINTAINING TRANSPLANTATION TOLERANCE IN ANTITHYMOCYTE GLOBULINTREATED RATS
34. Thrombectomy and in Situ Fibrinolysis in the Treatment of Acute Hepatic Arterial Thrombosis after Liver Transplantation in Two Children.
35. Mechanisms in experimental transplantation tolerance
36. HIGHER PREVALENCE OF END STAGE RENAL DISEASE (ESRD) AMONG LIVE KIDNEY DONORS THAN EXPECTED.
37. Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.